SCHEMBL4513470

SCHEMBL4513470

CC(C)c1noc(-c2ccc(N3CCN(CCC4CCN(C(=O)OC(C)(C)C)CC4)CC3)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 13/20 0.48
TGFBR1 P36897 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SYK P43405 1/20 0.41
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
PTK2 Q05397 1/20 0.40
CETP P11597 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4514841 0.85 GPR119 (0.49) GPR119TGFBR1
SCHEMBL4512479 0.82 GPR119 (0.62) GPR119JAK2
SCHEMBL4516915 0.80 GPR119 (0.54) GPR119TGFBR1MAPTMAPK1HTT
SCHEMBL13757774 0.79 GPR119 (0.48) GPR119TGFBR1SYKJAK2JAK3
SCHEMBL7366692 0.79 GPR119 (0.59) GPR119TGFBR1ALDH1A1MAPT
SCHEMBL13757755 0.78 GPR119 (0.58) GPR119TGFBR1NPC1ALDH1A1MAPT
SCHEMBL4509519 0.78 GPR119 (0.58) GPR119TGFBR1
SCHEMBL4504053 0.77 GPR119 (0.60) GPR119TGFBR1ALDH1A1MAPTHTT
SCHEMBL13757759 0.77 GPR119 (0.52) GPR119TGFBR1NPC1ALDH1A1MAPT
SCHEMBL4515782 0.76 GPR119 (0.74) GPR119TGFBR1ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203676-A1 G-protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-08-13 US disclosed
US-20090203676-A1 G-protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-08-13 US disclosed
US-20090203676-A1 G-protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-08-13 US disclosed
EP-1909791-A1 G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2008-04-16 EP disclosed
WO-2007003964-A1 G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed
WO-2007003964-A1 G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203676-A1 G-protein Coupled Receptor Agonists GPR119, GCGR, GPBAR1 GPR119 1/4885TGFBR1 834/4885NPC1 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.